News
Article
Author(s):
In case you missed it, this week we had news about results from BE HEARD I and BE HEARD II published in The Lancet, AbbVie's Clearly Me Campaign, the role of HIF-1-alpha in inflammation and psoriasis, and more.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.
Discover pearls on caring for patients with STDs, using dermatopathology in SOC, managing inflammatory skin conditions in women, and ensuring patients are able to access care needed.
In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.
Care Messenger helps to expand care delivery and respond to growing patient needs without placing additional strain on clinicians.
This week’s collection of the latest dermatologic studies includes case reports of onychocytic matricoma, congenital triangular alopecia treated with 5% topical minoxidil, systemic therapy usage in vulvar lichen sclerosus and vulvovaginal lichen planus, and dose escalation of interleukin inhibitors in Japanese patients with psoriasis.
Results of a recent study show RECAP's impact on adult Asian patients with AD.
A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.
Some states offer great homestead protection, but most provide an inadequate shield. Learn how to protect your greatest assets.
A large amount of studies included in the review centered around the use of botulinum toxin in these indications.
Ayesha Patrick: Advocacy, Representation, and Hope Via AbbVie's Clearly Me Campaign
Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.
A study out of Japan found some biologics used to treat psoriasis may require higher dose escalation than others.
This month's Legal Eagle column examines if patients have a legal property right to health care, given public funding of medical education.
Researchers from NYU Langone recently published a study clarifying the role of HIF-1-alpha in inflammation and psoriasis, which has been unclear until now.
VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.
While MMS is recognized as the gold standard for skin cancer treatment, numerous challenges still hinder widespread adoption and practice.
The new action date is December 29, 2024.
A new acne-specific HRQoL questionnaire developed in Europe could help to create more comprehensive, individualized treatment plans.
Scores for erythema, dryness, quality of life, and aesthetic improvement were all markedly improved in patients using tranexamic acid versus traditional therapy alone.
The Lancet data is the primary publication of bimekizumab results from BE HEARD I and BE HEARD II.
Tiffani Botts Massey, PA-C, Florida Society of Dermatology PAs President Elect, and Heather Gates, PA-C, the organization's current president, preview the upcoming conference.
Regional disparities were highlighted in a study of inpatient dermatology encounters, locations, and providers from 2013 to 2019.
The largest patient study across the continent found a direct link between the extent of hair loss and the negative impact on quality of life.
Earlier this week, we shared our third Skin Cancer Awareness Month quiz. Review the answers and your responses below.
Supplementation with RGLE led to clinically significant improvements in patients with acne vulgaris, according to a study.
Misinformation regarding the use of corticosteroids remains persistent and may have implications on patient care.
ICYMI: 5 news headlines that impact the treatment of scars, wounds, melanoma, and other skin conditions impacting veterans and active military personnel.